NASDAQ$GOCO

GoHealth Inc · Q1 2024 earnings

Q1 2024 earnings · · Investor relations

Briefing

GoHealth's first quarter results for 2024 were reported, highlighting exceeding expectations and strategic alignment with consumer-centric approach.

GoHealth reported a slight increase in net revenues to $185.6 million, with submissions increasing to 216,148. The company experienced a net loss of $21.3 million, an improvement from the prior year, and an Adjusted EBITDA of $26.9 million.

  • Net revenues increased slightly to $185.6 million compared to the prior year.
  • Submissions increased to 216,148 from 213,645 in the prior year period.
  • Net loss improved to $21.3 million from $22.5 million in the prior year period.
  • Adjusted EBITDA decreased slightly to $26.9 million.

Headline financials

Total Revenue

$186M

Previous: $183M+1.3%
EPS

-$1.04

Previous: -$1.12+7.1%
Adjusted EBITDA Margin

14.5%

No prior period
EBITDA

$22.8M

No prior period
Adjusted EBITDA

$26.9M

No prior period
Sales per Submission

$856.00

Previous: $794.00+7.8%
Direct Operating Cost per Submission

$640.00

No prior period
Submissions

216.1K

No prior period
Capital Expenditures

-$4.56M

No prior period
Free Cash Flow

-$9.22M

Previous: -$9.18M-0.4%
Net Income

-$9.22M

Previous: -$9.18M-0.4%
Operating Income

-$4.03M

Previous: -$5.75M+29.9%
Gross Profit

$148M

Previous: $138M+7.2%
Cash & Equivalents

$97.8M

Previous: $32.3M+202.6%
Total Assets

$1.4B

Previous: $1.54B-9.6%
Stock-Based Comp

$1.78M

Previous: $4.44M-59.9%

Revenue & EPS history

GoHealth · Revenue · Quarterly

$186M

Q1 2024+1.3%vs Q1 2023
Beat estimate in 5 of 14 quarters(36%)
ActualEstimate

Revenue by segment

GoHealth · $11.9M total across 4 segments · Q1 2026

  • Medicare Agency Revenue
    $9.8M
  • Other Non-Agency Revenue
    $1.76M
  • Medicare Non-Agency Revenue
    $200K
  • Other Agency Revenue
    $155K

Forward guidance

GoHealth is confident in its alignment with CMS guidelines and expects increased demand for its personalized Encompass shopping experience. The company remains committed to leveraging technology to improve healthcare decisions and drive profitability.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q1 2024

Historical avgQ1 2024

-7.7%

Avg return

Earnings day

-9.0%

Avg return

5 days after

-6.6%

Avg return

30 days after

26%

6 / 23 earnings

Positive

+32.2%

Q1 2023

Best reaction

-45.5%

Q2 2021

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-0.5%
Q3 2025-24.4%-32.0%-12.8%
Q2 2025-9.0%-7.6%-23.8%
Q1 2025-0.6%-17.4%-21.4%
Q4 2024-14.4%-14.9%-32.8%
Q3 2024-6.6%-0.4%-15.4%
Q2 2024-21.4%-28.3%-34.0%
Q1 2024-8.0%-11.1%+2.2%
Q4 2023-13.0%-25.7%-27.0%
Q3 2023+2.3%+6.7%+7.4%
Q2 2023+6.8%+6.3%-17.2%
Q1 2023+32.2%+44.8%+99.5%
Q4 2022-19.9%-6.2%-18.5%
Q3 2022-16.7%-9.4%+95.3%
Q2 2022-31.5%-43.3%-57.0%
Q1 2022+11.1%+4.9%+6.5%
Q4 2021+23.7%+37.7%-9.8%
Q3 2021+1.1%-4.7%-18.1%
Q2 2021-45.5%-42.2%-34.7%
Q1 2021-2.7%-5.6%-4.0%
Q4 2020-14.9%-16.9%-4.1%
Q3 2020-14.9%-15.1%+1.8%
Q2 2020-10.5%-18.5%-27.1%
Q1 2020
Q4 2019
Q2 2019
Q1 2019

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro